<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>OPUS 4 Latest Documents RSS Feed</title>
    <description>Latest documents</description>
    <link>http://publikationen.ub.uni-frankfurt.de/index/index/</link>
    <pubDate>Fri, 24 Apr 2009 12:02:33 +0200</pubDate>
    <lastBuildDate>Fri, 24 Apr 2009 12:02:33 +0200</lastBuildDate>
    <item>
      <title>Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer : a multicentre prospective randomized trial</title>
      <link>http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/6369</link>
      <description>Background The effect of additional treatment strategies with antineoplastic agents on intraperitoneal tumor stimulating interleukin levels are unclear. Taurolidine and Povidone-iodine have been mainly used for abdominal lavage in Germany and Europe. Methods In the settings of a multicentre (three University Hospitals) prospective randomized controlled trial 120 patients were randomly allocated to receive either 0.5% taurolidine/2,500 IU heparin (TRD) or 0.25% povidone-iodine (control) intraperitoneally for resectable colorectal, gastric or pancreatic cancers. Due to the fact that IL-1beta (produced by macrophages) is preoperatively indifferent in various gastrointestinal cancer types our major outcome criterion was the perioperative (overall) level of IL-1beta in peritoneal fluid. Results Cytokine values were significantly lower after TRD lavage for IL-1beta, IL-6, and IL-10. Perioperative complications did not differ. The median follow-up was 50.0 months. The overall mortality rate (28 vs. 25, p = 0.36), the cancer-related death rate (17 vs. 19, p = .2), the local recurrence rate (7 vs. 12, p = .16), the distant metastasis rate (13 vs. 18, p = 0.2) as well as the time to relapse were not statistically significant different. Conclusion Reduced cytokine levels might explain a short term antitumorigenic intraperitoneal effect of TRD. But, this study analyzed different types of cancer. Therefore, we set up a multicentre randomized trial in patients undergoing curative colorectal cancer resection. Trial registration : ISRCTN66478538</description>
      <author>Chris Braumann; Carsten Nils Gutt; Johannes Scheele; Charalambos Menenakos; Wilhelm Willems; Joachim M. Müller; Christoph A. Jacobi</author>
      <category>article</category>
      <guid>http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/6369</guid>
      <pubDate>Fri, 24 Apr 2009 12:02:33 +0200</pubDate>
    </item>
  </channel>
</rss>
